Ziprasidone augmentation of escitalopram for major depressive disorder: Efficacy results from a randomized, Double-Blind, Placebo-Controlled Study

American Journal of Psychiatry

Volumn 172, Issue 12, 2015, Pages 1251-1258

  Papakostas, George I ^a,b,c   Fava, Maurizio ^a,b,c   Baer, Lee ^a,b,c   Swee, Michaela B ^a,b,c   Jaeger, Adrienne ^a,b,c   Bobo, William V ^a,b,c   Shelton, Richard C ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO; ZIPRASIDONE; ANTIDEPRESSANT AGENT; CITALOPRAM; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MUSCLE TWITCH; NAUSEA; OPEN STUDY; PAIN; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WEIGHT GAIN; XEROSTOMIA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED;

ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 84949200946     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14101251     Document Type: Article

References (33)

1. Papakostas GI, Fava M: Monoamine-based pharmacotherapy, in Biology of Depression: From Novel Insights to Therapeutic Strategies. Edited by Licinio J, Wong ML. Weinheim, Germany, Wiley-VCH Verlag, 2005, pp 87-140
2. Papakostas GI, FavaM: Does the probability of receiving placebo influence clinical trial outcome?Ameta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19:34-40
3. PapakostasGI:Managing partial response or nonresponse: Switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70(suppl 6):16-25
4. Shelton RC, Papakostas GI: Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 2008; 117:253-259
5. Papakostas GI: Augmentation strategies in the treatment of major depressive disorder: Examining the evidence on augmentation with atypical antipsychotics. CNS Spectr 2007; 12(suppl 22): 10-12
6. Papakostas GI: Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. Essent Psychopharmacol 2005; 6: 209-220
7. Papakostas GI, Shelton RC, Smith J, et al: Augmentation of antidepressants with atypical antipsychotic medications for treatmentresistantmajor depressive disorder: Ameta-analysis. J Clin Psychiatry 2007; 68:826-831
8. Nelson JC, Papakostas GI: Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980-991
9. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci 2000; 68:29-39
10. Tatsumi M, Jansen K, Blakely RD, et al: Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368:277-283
11. Schmidt AW, Lebel LA, Howard HR Jr, et al: Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425:197-201
12. Papakostas GI, Petersen TJ, Nierenberg AA, et al: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65:217-221
13. Silverstone PH, Salinas E: Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001; 62:523-529
14. Lunn MP, Hughes RA, Wiffen PJ: Duloxetine for treating painful neuropathy, chronic pain, or fibromyalgia. Cochrane Database Syst Rev 2014; 1:CD007115
15. First BM, Spitzer RL, Gibbon M, et al: Structured Clinical InterviewforDSM-IVAxis IDisorders, PatientEdition (SCIDI/P). New York, New York State Psychiatric Institute, Biometrics Research, 1995
16. Trivedi MH, Rush AJ, Ibrahim HM, et al: The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 2004; 34:73-82
17. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960a; 23:56-62
18. GuyW(ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
19. Fawcett J, Epstein P, Fiester SJ, et al: Clinical management: Imipramine/placebo administration manual. Psychopharmacol Bull 1987; 23:309-324
20. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
21. DeLoach LJ, Higgins MS, Caplan AB, et al: The visual analog scale in the immediate postoperative period: Intrasubject variability and correlation with a numeric scale. Anesth Analg 1998; 86:102-106
22. Thase ME, Trivedi MH, Nelson JC, et al: Examining the efficacy of adjunctive aripiprazole in major depressive disorder: A pooled analysis of 2 studies. PrimCare Companion J Clin Psychiatry 2008; 10:440-447
23. Iovieno N, Papakostas GI: Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder? J Clin Psychiatry 2012; 73:676-683
24. IovienoN, PapakostasGI: Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: A meta-analysis. J Clin Psychiatry 2012; 73: 1300-1306
25. Papakostas GI, ∅stergaard SD, Iovieno N: The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 2015; 76:456-466
26. FavaM, Rush AJ, Alpert JE, et al: Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR∗D report. Am J Psychiatry 2008; 165:342-351
27. Papakostas GI, Clain A, Ameral VE, et al: Fluoxetine-clonazepam cotherapy for anxious depression: An exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol 2010; 25:17-21
28. Papakostas GI, Fan H, Tedeschini E: Severe and anxious depression: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2012; 22:347-355
29. Citrome L: Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: An analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010; 122:39-48
30. Marcus RN, McQuade RD, Carson WH, et al: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28:156-165
31. Berman RM, Marcus RN, Swanink R, et al: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:843-853
32. Berman RM, Fava M, Thase ME, et al: Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14:197-206
33. Dunner DL, Amsterdam JD, Shelton RC, et al: Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study. J Clin Psychiatry 2007; 68:1071-1077